An agenda for UK clinical pharmacology: Integrating pharmacology and clinical pharmacology in pharmaceutical companies
Article first published online: 8 MAY 2012
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
British Journal of Clinical Pharmacology
Special Issue: Agenda for Clinical Pharmacology Issue
Volume 73, Issue 6, pages 927–930, June 2012
How to Cite
Hunter, J. A. (2012), An agenda for UK clinical pharmacology: Integrating pharmacology and clinical pharmacology in pharmaceutical companies. British Journal of Clinical Pharmacology, 73: 927–930. doi: 10.1111/j.1365-2125.2012.04239.x
- Issue published online: 8 MAY 2012
- Article first published online: 8 MAY 2012
- Accepted manuscript online: 23 FEB 2012 05:03AM EST
- RECEIVED; 13 January 2012; ACCEPTED; 30 January 2012; ACCEPTED ARTICLE PUBLISHED ONLINE; 23 February 2012
Integration of clinical and preclinical pharmacology in pharmaceutical companies could be improved by several key recommendations:
Companies should ensure that there is an adequate pool of trained clinical pharmacologists and preclinical pharmacologists. Training should include topics that allow clinical pharmacologists to be cognizant of the methods, issues and challenges faced by the preclinical pharmacologists and vice versa.
Companies should incentivize such integration internally by aligning objectives and metrics/incentives.
In academic medicine and the NHS there should be support for involvement of clinical pharmacologists in basic academic research and industrial R & D and new ways of facilitating and incentivizing preclinical pharmacologists and clinical pharmacologists to move between these various environments should be sought.